Heteroalkyne compounds of formula (I) or pharmaceutically acceptable salts thereof wherein ring A is selected from a phenyl, a five-membered heteroaryl, a six-membered heteroaryl, a 5,6-or 6,6-bicyclic heteroaryl, and 5,6- or 6,6-bicyclic heterocycle any of which may be optionally substituted； ring B is selected from a phenyl, a five-membered heteroaryl, a six-membered heteroaryl, and a 5,6-bicyclic heteroaryl any of which may be optionally substituted； L is a linker as herein defined； each of RN1 and RN2 are independently hydrogen, an optionally substituted C1-6alkyl, or an optionally substituted C3-6carbocyclyl, or RN1 and RN2 are taken with the intervening nitrogen to form an optionally substituted heterocyclic moiety； and t is 1, 2 or 3. In particular, the compounds act as inhibitors of the MAP kinase interacting kinases 1 and 2 (MNK1 and MNK2) and/or Abelson (Abl)-tyrosine kinase. The compounds are useful in treating diseases associated with aberrant or dysregulation of the corresponding pathway, preferably in the prevention or treatment of conditions including cancer, (such as solid tumour and haematological tumour), an inflammatory disease, a neurodegenerative disease (such as Alzheimers disease), or a metabolic disorder (such as diabetes, hyperlipidemia and obesity).
